[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354045-105":59,"doc-detail-354045-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","reprogramming-car-t-cells-across-genetic-epigenetic-metabolic-and-microenvironmental-axes-to-improve-efficacy-and-safety-in-cancer-and-autoimmune-disease","Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune disease","","CAR T-cell therapy achieves durable remissions in several hematologic cancers, but solid tumors and immune-mediated diseases face recurring limitations: insufficient antigen specificity, impaired trafficking, progressive dysfunction during chronic stimulation, and toxic inflammatory syndromes. For autoimmune settings, risks are higher relative to acceptable tolerance thresholds, since even “on-target” effects can drive long-term immunodeficiency. This review frames CAR T optimization as multi-layer reprogramming across genetic circuitry, epigenetic state, metabolism, and tissue microenvironment, proposing failure-mode–driven design to improve both efficacy and safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reprogramming-car-t-cells-across-genetic-epigenetic-metabolic-and-microenvironmental-axes-to-improve-efficacy-and-safety-in-cancer-and-autoimmune-disease/354045/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reprogramming-car-t-cells-across-genetic-epigenetic-metabolic-and-microenvironmental-axes-to-improve-efficacy-and-safety-in-cancer-and-autoimmune-disease/354045.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR T activity limited in solid tumors and immune-mediated diseases?","Question",{"text":112,"@type":113},"Limitations include imperfect antigen specificity, inadequate trafficking, progressive dysfunction under chronic stimulation, and toxic inflammatory syndromes such as CRS and ICANS.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes autoimmune applications of CAR T especially challenging?",{"text":117,"@type":113},"Acceptable risk is lower than in cancer, and “on-target” effects may still be clinically unacceptable if they create long-term immunodeficiency.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategy does the review propose to improve both efficacy and safety?",{"text":121,"@type":113},"It emphasizes disciplined, failure-mode–driven design using programmable antigen logic, epigenetic programming that preserves renewable functional states, metabolic rewiring under physiologic stress, and microenvironment-aware access and local control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354045,1790464886,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Mini Review  \nPUBLISHED 07 April 2026  \nDOI 10.3389/fimmu.2026.1806459  \nOPEN ACCESS  \nEDITED BY  \nDavid L. Wiest,  \nFox Chase Cancer Center, United States  \nREVIEWED BY  \nStephen Hatﬁeld,  \nNortheastern University, United States  \n*CORRESPONDENCE  \nMarc Scherlinger  \n [marc.scherlinger@chru-strasbourg.fr](marc.scherlinger@chru-strasbourg.fr)  \nRECEIVED 07 February 2026  \nREVISED 20 March 2026  \nACCEPTED 23 March 2026  \nPUBLISHED 07 April 2026  \nCITATION  \nScherlinger M (2026) Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efﬁcacy and safety in cancer and autoimmune disease.  \nFront. Immunol. 17:1806459 .  \ndoi: 10.3389/fimmu.2026.1806459  \nCOPYRIGHT  \n© 2026 Scherlinger. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nReprogramming CAR  \nT cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efﬁcacy and safety in cancer and autoimmune disease  \nMarc Scherlinger 1,2*  \n1 Rheumatology Department, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, 2 UMR Inserm 1109 Immuno-Rhumatologie Mole´ culaire, Centre de recherche en biome´ decine de Strasbourg (CRBS), Strasbourg, France  \nCAR T-cell therapy has delivered durable remissions in several hematologic cancers, yet activity in solid tumors and extension to immune-mediated diseases remain constrained by recurring failure modes: imperfect antigen speciﬁcity, inadequate trafﬁcking, progressive dysfunction under chronic stimulation, and toxic inﬂammatory syndromes. Early reports of CAR-based immune “resets” in refractory autoimmune disease amplify both promise and stakes, because acceptable risk is lower than in cancer and “on-target” effects may still be clinically unacceptable if they create long-term immunodeﬁciency. This review treats CAR T optimization as multi-layer reprogramming across genetic circuitry, epigenetic state, metabolism, and the tissue microenvironment. We argue that many celebrated single-layer upgrades (stronger signaling, checkpoint deletion, constitutive cytokine armoring) often trade one failure mode for another. Instead, the most credible path to simultaneously improving efﬁcacy and safety is disciplined, failure-mode–driven design: (i) programmable antigen logic and titratable activation to reduce off-tissue damage; (ii) epigenetic programming that preserves renewable functional states without removing essential restraints; (iii) metabolic rewiring evaluated under physiologic stress conditions; and (iv) microenvironment-aware strategies that prioritize access and local control over brute-force potency.  \nKEYWORDS  \nautoimmunity, CAR T cells, CAR-Treg, exhaustion, genome editing, immunometabolism, safety switches, tumor microenvironment  \n1 Introduction  \nChimeric antigen receptor (CAR-) T cells are living therapeutics whose behavior reﬂectsthe integration of receptor signaling, differentiation state, and environmental stress. Their clinical impact in B-cell malignancies established that redirected T cells can eradicate large disease burdens, but the same platform has struggled in most solid tumors where antigen heterogeneity, physical exclusion, suppressive cytokines, and nutrient deprivation combine  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nto blunt function (1–3) . Toxicities remain a second, independent ceiling: cytokine release syndrome (CRS) and immune effector cell– associated neurotoxicity syndrome (ICANS) emerge from inﬂammatory ampliﬁcation loops that can be unpredictab","cbCaipqVMaBXC2BT","https://ap.wps.com/l/cbCaipqVMaBXC2BT","pdf",1370290,"English","# Introduction\n## CAR T optimization as multi-layer reprogramming\n## Failure-mode–driven design principles","[{\"question\":\"Why is CAR T activity limited in solid tumors and immune-mediated diseases?\",\"answer\":\"Limitations include imperfect antigen specificity, inadequate trafficking, progressive dysfunction under chronic stimulation, and toxic inflammatory syndromes such as CRS and ICANS.\"},{\"question\":\"What makes autoimmune applications of CAR T especially challenging?\",\"answer\":\"Acceptable risk is lower than in cancer, and “on-target” effects may still be clinically unacceptable if they create long-term immunodeficiency.\"},{\"question\":\"What strategy does the review propose to improve both efficacy and safety?\",\"answer\":\"It emphasizes disciplined, failure-mode–driven design using programmable antigen logic, epigenetic programming that preserves renewable functional states, metabolic rewiring under physiologic stress, and microenvironment-aware access and local control.\"}]","Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune disease | PDF",1790108579,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af79841ebc75b111e5a9329a334aa59a.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f626396794ee8be5eaf604ce817ea08c.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/950718889e76c9ad860299f5fcd3dff2.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f599ae2c73b36ac26d86c46a2bfd966.webp",980,1385]